Vendor Intelligence Report: Xian Yihang Technology

Published 3 Jul 2026. 25-page investigative report on who is behind Xian Yihang Technology: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 3 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 71 Finnrick lab tests, Xian Yihang Technology records 51 pass / 20 fail, for an overall pass rate of 72%. The record is uneven rather than uniformly weak: GHK-Cu and Tirzepatide are the relative bright spots, while Tesamorelin and especially TB-500 are the products most likely to push a buyer toward another source or fresh lot-level testing. The report also shows how ratings move under stricter purity and fill thresholds.

The vendor is not a single clean storefront. Finnrick attributes the listing to a Xi'an supplier cluster spanning an active eCHEMI shop, Yihang Biochemical's B2B site, LookChem records, and the TopXPeptide / YH Peptide retail brand. Shared email infrastructure, recurring contact data, a named management contact, and Chinese facility signage support the link; shareholder-level proof remains unresolved because registry access was blocked.

The non-lab story is about continuity and verification. The original eCHEMI shop is gone with no public archive; the active platform profile says 2024 while one product listing carried an older founding claim; and a dissolved same-name-adjacent company remains an open predecessor lead. Certification claims and a broader catalog that includes pharmaceutical compounds are documented, but the certificates and regulatory clearance were not verified.

Inside the full report:

  • Per-product Finnrick pass/fail rates, trajectory charts, and methodology-divergence analysis for all 6 tested products
  • Attribution map linking eCHEMI shop IDs, yihangbec.com, topxpeptide.com, xayhang.com, and YH Peptide aliases
  • Contact and personnel exhibits covering Sam Zhang, LookChem, LinkedIn, TikTok, Reddit, Janoshik, and DisclosedLabs records
  • Timeline of the defunct first eCHEMI shop, current Chemical listing, domain registrations, and Wayback captures
  • Certification and regulatory-scope review of ISO/FSSC/Halal/FAMI-QS claims and drug-catalog items
  • Open leads on Chinese registry/USCC records, the dissolved 2016 entity, xayhang.com registrant data, and import-record searches

Risk assessment

  • TB-500 and Tesamorelin quality risk — high: TB-500 is 39.5% with 4 tests split 2 pass / 2 fail; Tesamorelin is 50.08% with 7 tests and 4 pass / 3 fail.
  • Retatrutide and BPC-157 lot-verification risk — medium: Retatrutide is 70.66% on 21 tests; BPC-157 has 4 passes but only a 60.95% rating and thin evidence depth.
  • Corporate opacity and channel-verification risk — medium: Multiple Yihang/TopXPeptide/YH Peptide aliases, no USCC or official-channel list found, and the original eCHEMI shop is now 404.
  • Certification-verification risk — medium: Yihang claims ISO/FSSC/Halal/FAMI-QS credentials, but no certificate numbers, issuing bodies, or public registry matches were found.
  • Regulatory-scope risk — high: The eCHEMI catalog includes pharmaceutical compounds such as Erdafitinib, Orforglipron and Tesofensine without verified export/regulatory clearance.